TNF and Sepsis: Although previous clinical trials of TNF-α monoclonal antibodies have not shown overall benefit in unselected sepsis populations [40], our findings suggest that patient stratification into the inflammatory endotype might identify a subgroup more likely to benefit from these targeted therapies.